Dr Aggarwal joined in January 2023 as Senior Vice President, Medical Affairs.
Dr Aggarwal brings more than 20 years of experience spanning large pharma with multiple commercial products to small pharma with a single asset. Over her career, she has led medical affairs support of clinical development, pre-launch and launch planning as well as life cycle management. Prior to Verona Pharma, Dr Aggarwal built a new Medical Affairs organization at BioCryst Pharmaceuticals to launch the company’s first commercialized product and most recently served as VP, Global Commercial Pipeline Strategy, where she led commercialization strategy for all pipeline assets. Previously, Dr Aggarwal was Vice President, Medical Affairs at Dova Pharmaceuticals where she built and led the medical affairs function through two product launches.
Dr Aggawal has also held roles of increasing responsibility in medical affairs at Stealth BioTherapeutics, Cempra Pharmaeuticals, BPL, Salix Pharmaceuticals and GlaxoSmithKine.
Dr Aggawal holds a BS in biochemistry from North Carolina State University and a PharmD from the University of North Carolina at Chapel Hill.
